coiaward2010

The CML Advocates Network participating at ESH 2017

esh footerThe 19th Annual John Goodman Conference on Chronic Myeloid Leukemia: Biology and Therapy were held in Estoril, Portugal on12-15 October 2017 organized by the European School of Haematology (ESH).

This event gathers leading scientists in the field of Chronic Myeloid Leukemia treatment including Clinicians as well as Biologists and Medical laboratory technologists.

Although the Programme does not contain specific Patient Advocacy sessions like in other scientific congresses, several patient advocates from different countries have been attending the conference. A number of CML advocates have been participating at this conference and sharing our CML patient's perspective.

 

This year, the Programme was focused on informative and intriguing topics such as "Stem Cells and the Microenvironment", "Molecular Biology and New Targets", "CML-BP and Mechanisms of Transformation", "Resistance and New Targets", "Biomarkers", "Adherence" and "Treatment-Free Remission".

CML Advocates Network longtime member and also former steering committee member Rita Christensen, President of the Patient Advocacy Group for Lymphoma, Leukemia and MDS from Denmark presented her personal experience as a patient living with CML for 20 years.

esh1Our Co-founder Jana Pelouchova and President of, "Diagnóza Leukemie", Czech Republic, was presenting the Abstract "Factors Influencing Adherence in CML and Ways to Improvement: Results of a Patient-Driven Survey of 2546 Patients in 63 Countries". The Abstract was selected by the European School of Haematology (ESH) to be presented this year that summarized the successful study that we conducted during 2012 and 2013 enrolling 2151 CML patients from 79 patient organisations worldwide. 

There is clear evidence that survival of CML patients is close to the age-matched general population and also the quality of life in the general population is similar for most CML patient groups when CML is treated effectively in chronic phase with current therapies. However, every fifth patient is classified as having “low adherence” according to the Morisky Medication Adherence Scale (MMAS).

Our study concluded that not a single factor is responsible for adherence and prediction is difficult but there are some factors emerging as highly relevant. The main factors that can be influenced at least partially are the quality of the doctor-patient relationship, management of side effects and the number of doses per day.

On March 2017 our paper based on this study was published in the Journal of Cancer Research and Clinical Oncology, "Geissler, J., Sharf, G., Bombaci, F. et al. J Cancer Res Clin Oncol (2017). doi:10.1007/s00432-017-2372-z”.

Our Abstract Presentation "Factors Influencing Adherence in CML and Ways to Improvement: Results of a Patient-Driven Survey of 2546 Patients in 63 Countries" is available HERE

 


 
   
 

Please donate!

Please donate!

LogIn